Another exciting approach showed that S100A6 levels decrease in human breast cancer cell line MDA-MB-231 when treated with anti-tumour agents, namely tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and etoposide, indicating that S100A6 might be a potential biomarker for apoptosis during therapy [100]. This evidence concerns the gene S100A6 and breast carcinoma.